How Much Does Rapamycin (Sirolimus) Cost in Delaware in 2026?

Delaware Retail Pharmacy Prices for Sirolimus

The average cash price for generic sirolimus at Delaware retail pharmacies sits near $80 per month in 2026, based on 30-day supplies of 1 mg or 2 mg tablets. This represents a steep drop from the Pfizer-branded Rapamune list price of roughly $600 per month. The difference reflects the mature generic market: sirolimus lost patent exclusivity years ago, and the FDA Orange Book lists multiple approved ANDA holders including Greenstone and Zydus [1].

Why Cash Prices Vary by Pharmacy

Prices at Delaware's independent pharmacies, Walgreens locations, and CVS outlets can differ by 30% or more for the same generic tablet. Pharmacy benefit middlemen negotiate different acquisition costs, and some chains add higher dispensing fees. Patients paying out of pocket should call at least three pharmacies before filling.

Comparing Delaware to National Averages

Delaware's $80 average tracks close to the national generic mean. A 2023 analysis of mTOR inhibitor prescribing patterns found that generic sirolimus wholesale acquisition cost had dropped below $3 per tablet for 1 mg strength [2]. Rural pharmacies in Sussex County may charge slightly more than urban Wilmington locations due to lower prescription volume and higher overhead per fill.

Sirolimus pricing also depends on dose. Transplant patients taking 2 mg daily pay roughly double what an off-label longevity user taking 5 mg once weekly would pay, since the weekly user needs only four to five tablets per month rather than thirty [3].

Sirolimus Insurance Coverage in Delaware

Private Insurance and Formulary Placement

Most commercial insurance plans available through the Delaware Health Insurance Marketplace list generic sirolimus on Tier 2 or Tier 3 formularies. Copays typically range from $15 to $50 per month. Plans from Highmark Blue Cross Blue Shield of Delaware and Aetna, the two largest individual-market carriers in the state, generally cover sirolimus for FDA-approved transplant indications without step therapy [4].

Off-label prescribing for longevity or anti-aging purposes is a different story. Insurers rarely cover off-label sirolimus, and appeals for coverage outside transplant rejection or lymphangioleiomyomatosis (LAM) are almost always denied. The FDA-approved prescribing information limits the indication to prophylaxis of organ rejection in renal transplant patients aged 13 and older, in combination with cyclosporine and corticosteroids, and to treatment of LAM [5].

Delaware Medicaid

Delaware Medicaid covers sirolimus with prior authorization. The state's Medicaid program, administered through Delaware Health and Social Services, requires prescribers to document an FDA-approved indication or provide clinical justification for off-label use. Prior authorization requests typically take 24 to 72 hours for review [6].

For transplant patients on Delaware Medicaid, sirolimus copays are minimal, often $1 to $3 per prescription per federal Medicaid cost-sharing rules. Patients who have received a kidney transplant and qualify for both Medicare and Medicaid may also access sirolimus through Medicare Part B's immunosuppressive drug benefit, which was expanded by the Consolidated Appropriations Act of 2021 to cover transplant drugs indefinitely after kidney transplant [7].

Medicare Part D

Medicare Part D plans in Delaware generally cover generic sirolimus. During the coverage gap (the so-called "donut hole"), patients now benefit from the Inflation Reduction Act's $2,000 annual out-of-pocket cap, which took full effect in 2025. For a drug costing $80 per month retail, most Medicare beneficiaries will reach that cap only if they take several other brand-name medications simultaneously [8].

Compounded Sirolimus in Delaware

503A Pharmacy Access

Compounded sirolimus is available in Delaware through licensed 503A pharmacies. These pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits compounding by a licensed pharmacist based on a valid patient-specific prescription [9]. Delaware's Board of Pharmacy oversees 503A compliance within the state.

Compounded sirolimus typically costs around $120 per month in Delaware. This is higher than the generic retail price because compounding pharmacies prepare custom formulations (topical creams, low-dose capsules, or liquid suspensions) not available as manufactured generics. Patients seeking rapamycin in non-standard doses, such as 1 mg or 3 mg capsules for weekly longevity protocols, sometimes prefer compounded preparations for dosing convenience.

503B Outsourcing Facilities

Some Delaware prescribers also source sirolimus from FDA-registered 503B outsourcing facilities, which can produce larger batches without patient-specific prescriptions. The FDA maintains a public list of registered 503B facilities and publishes inspection results [10]. Patients should verify that any compounding pharmacy or outsourcing facility they use holds current FDA registration and state licensure.

Off-Label Longevity Use and Cost Implications

The Evidence Base

Interest in rapamycin for longevity has grown rapidly. Sirolimus inhibits mTOR (mechanistic target of rapamycin), a nutrient-sensing kinase that regulates cell growth, autophagy, and aging pathways. Preclinical data in mice showed that rapamycin extended median lifespan by 9% to 14% when started even in late life, according to findings from the National Institute on Aging's Interventions Testing Program published in Nature [11].

Human data remain limited but are accumulating. The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity), published in Aging Cell in 2024, enrolled healthy adults aged 50 to 85 and tested low-dose rapamycin versus placebo over 12 months. The trial found rapamycin was well-tolerated at weekly doses, with adverse event rates comparable to placebo [12]. Larger, longer trials are needed before any longevity indication could receive FDA approval.

What Off-Label Users Pay in Delaware

Because insurers do not cover off-label longevity use, Delaware patients pursuing this route pay entirely out of pocket. A typical weekly protocol of 5 mg to 6 mg sirolimus requires about 20 to 24 tablets of 1 mg per month, costing $60 to $100 at generic cash prices. Some clinicians prescribe 2 mg tablets taken once weekly, which brings the monthly cost down to roughly $10 to $15 for four tablets at generic pricing.

The Marczyk et al. (2023) review in GeroScience summarized the rationale for intermittent low-dose mTOR inhibition in humans, noting that weekly dosing may reduce immunosuppressive side effects seen with daily transplant-dose regimens [13]. The dose-cost relationship matters: lower doses cost less and may carry fewer risks, though clinical benefit for aging remains unproven in large randomized trials.

How to Reduce Sirolimus Costs in Delaware

Manufacturer and Generic Savings Programs

Pfizer offers a savings card for branded Rapamune that can reduce copays for commercially insured patients, though it excludes government insurance (Medicare, Medicaid, Tricare). Generic manufacturers do not typically offer patient savings cards, but the low generic price makes this less critical [14].

Prescription Discount Cards

GoodRx, RxSaver, and SingleCare all list sirolimus coupons that can bring the price below $50 per month at participating Delaware pharmacies. These discount programs are free to use and work for uninsured and underinsured patients. They function as pharmacy benefit cards, not insurance, so they cannot be combined with an insurance copay.

Pill Splitting

For patients prescribed 2 mg daily or 2 mg weekly, purchasing 2 mg tablets and splitting them can cut costs roughly in half. Sirolimus tablets are scored for splitting. Patients should confirm with their pharmacist that splitting is appropriate for their specific generic manufacturer's formulation, as some coatings may not split evenly.

340B Drug Pricing

Delaware has multiple 340B-eligible health centers, including Westside Family Healthcare and La Red Health Center. These federally qualified health centers purchase drugs at steep discounts under the 340B Drug Pricing Program and may pass savings to eligible patients [15]. Uninsured patients and those below 200% of the federal poverty level should ask whether their health center participates.

Telehealth Prescribing of Sirolimus in Delaware

Delaware permits telehealth prescribing of sirolimus with no geographic restriction within the state. The Delaware Telehealth Act allows licensed prescribers to evaluate patients via synchronous audio-video and issue prescriptions for non-controlled substances, which includes sirolimus. Patients do not need to establish an in-person relationship first [16].

How Telehealth Affects Cost

Telehealth consultations for off-label rapamycin typically cost $100 to $250 for an initial visit and $75 to $150 for follow-ups. Several national longevity-focused telehealth platforms serve Delaware patients. Combining a telehealth consultation with generic pharmacy pricing can keep total out-of-pocket costs (visit plus medication) under $150 per month for a weekly low-dose protocol.

Monitoring Requirements

Regardless of prescribing modality, sirolimus requires periodic blood monitoring. Trough levels, complete blood counts, lipid panels, and renal function tests are standard. The FDA label recommends monitoring sirolimus trough concentrations, targeting 12 to 20 ng/mL in transplant patients during months 2 through 12 post-transplant [5]. Off-label longevity protocols typically target much lower troughs or simply use fixed low-dose weekly regimens without trough monitoring, though practice varies by clinician.

A 2020 systematic review published in The Lancet Healthy Longevity found that mTOR inhibitors at low doses improved immune function in older adults, with a 40% reduction in infection rates in the everolimus arm of the Mannick et al. Trial [17]. Monitoring costs (lab draws plus interpretation) add $50 to $150 per quarter depending on insurance status.

Side Effects That Drive Hidden Costs

Sirolimus can cause mouth ulcers, hyperlipidemia, cytopenias, and impaired wound healing. The prescribing information carries a boxed warning about increased susceptibility to infection and possible lymphoma development in immunosuppressed patients [5]. These risks are dose-dependent and most relevant at daily transplant doses.

Lipid Monitoring Costs

Sirolimus-induced hyperlipidemia occurs in 38% to 57% of transplant recipients, per registry data published in the American Journal of Transplantation [18]. Patients who develop elevated LDL cholesterol may need statin therapy, adding $4 to $20 per month for generic atorvastatin or rosuvastatin. Lipid panel testing costs $20 to $50 per draw without insurance.

Oral Ulcers and Dose Adjustments

Aphthous ulcers affect approximately 60% of patients on daily sirolimus at transplant doses, based on data from the Cochrane Database of Systematic Reviews analysis of mTOR inhibitor side effects [19]. At weekly low doses used off-label, the incidence appears much lower, though prospective data are sparse. Dose reduction or temporary discontinuation resolves most cases without additional cost.

Delaware-Specific Regulatory Considerations

Delaware does not impose additional state-level restrictions on sirolimus prescribing beyond standard DEA and FDA requirements. Sirolimus is not a controlled substance. Delaware pharmacists may substitute an AB-rated generic for branded Rapamune unless the prescriber writes "dispense as written" (DAW) on the prescription, per Delaware Code Title 24, Chapter 25 [20].

For compounded preparations, the Delaware Board of Pharmacy requires 503A pharmacies to maintain proper documentation of each patient-specific prescription. Out-of-state 503A pharmacies shipping into Delaware must hold a non-resident pharmacy license from the Board.